BWI: Mass Spectrometery is Emerging as Important Tool in Medical Applications and Diagnostics a Study by Dr. Puneet Chandna

Press release from Business Wire India
Source: AceProbe
Monday, November 07, 2011 04:41 PM IST (11:11 AM GMT)
Editors: Business: Business services, Healthcare, biotechnology & pharmaceutical; Technology; Healthcare
--------------------------------------------------
Mass Spectrometery is Emerging as Important Tool in Medical Applications and Diagnostics a Study by Dr. Puneet Chandna


New Delhi, Delhi, India, Monday, November 07, 2011 -- (Business Wire India) -- In a recent study that compared technologies for detection of the Human Papilloma Virus (HPV), compared three methods to include detection through DNA, RNA and Multiplexed- simultaneous detection of HPV genotypes by MALDI-TOF Mass spectrometry. The study revaluated the sensitivity and specificity of the mass spectrometry to be able to pick up mixed strains across 15 high-risk types of HPV. Potential validation on the India population makes the assay more reliable and informed choice for the diverse Indian populations.

In India Cervical Cancer is the largest killer of women and the incidence has surpassed that of breast cancer. World health organization recently reported that there are about 73,000 deaths annually in India due to cervical cancer and about 1,34,000 new cases are reported each year. Thankfully, this can be detected and reported on time with use of better cutting edge technology. MALDI-TOF mass spectrometry is one such technology. An important part of this technology is Molecular Diagnostics (MDx) and Personalized Genetic Solutions (PGx) that are regarded as the self validating tool due to its absolute nature of detection and reporting besides the sensitivity it offers over the conventional assays and tests.

Worldwide, the technology has widely been validated as an important tool for investigations in a clinical setting across pathways of cancer, cardiovascular diseases, pre-natal disorders and is extremely useful in infectious disease applications of identification and detection of viruses and bacteria.Centers such as Dana Faber, Roswell Park, Memorial Sloan Kettering Cancer Centre, Mayo Clinic etc. are some of the first to embrace the technology.

Genetic Testing is now available to the physicians in India, who can now take benefits of the technology from a range of assays suitable for HPV genotype analysis in Cervical Cancer, Breast Cancer assays for therapy selection & monitoring, pre-natal testing for hemoglobinopathies and influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with a drug's efficacy or toxicity.

Going forward, are in the process of validation & completion - a wide range of the assays for Cardiology, Oncology, Infectious diseases, Nutrition and others Genetics Disorders to be unveiled, to suit India's large population size, complex demographic history, and unique social structure.

About Dr. Chandna's,

Dr. Puneet Chandna -a PhD in biophysics has 2 decades of experience in the BioAnalytical sphere. Dr Chandna is an expert in evaluation, prognosis & management of symptoms and side effects in the field of Cardiology, Oncology, Diabetes and Nutrition.

Dr. Chandna is Managing Director at AceProbe Technologies (India) Pvt. Ltd, (fallout of a NASDAQ listed Company in India) a company conceptualized about a decade ago to stand out as a leader in Technology and strong IP driven organization in personalized medicine through healthcare Genomics.


CONTACT DETAILS
Dr. Puneet Chandna, Ph.D, F.I.E.T,C.Eng,, AceProbe Technologies (India) Pvt. Ltd., +91 (11) 45098118, puneet@aceprobe.com

KEYWORDS
BUSINESS SERVICES, HEALTHCARE, TECHNOLOGY, HEALTHCARE

If you wish to change your Business Wire India selection please click on this link http://www.businesswireindia.com/media/news.asp and use your personal username and password to login.

Submit your press release at http://www.businesswireindia.com